Table 3. Differences in oncologist- and patient-assessed performance status (PS) scores in relation to disease stage, type and sex of patient.
|
Doctor-assessed PS score compared to patient assessed PS score |
|||
|---|---|---|---|
| Group/subgroup (n) | Under-rated (D<P) n (%) | Agree (D=P) n (%) | Over-rated (D>P) n (%) |
| All patients (101) | 27 (27) | 51 (50) | 23 (23) |
| Females (29) | 3 (10) | 16 (55) | 10 (35) |
| Males (72) | 24 (33) | 35 (49) | 13 (18) |
| NSCLC | |||
| Stage unknown (1) | 1 (100) | – | – |
| Stage I (18) | 5 (28) | 9 (50) | 4 (22) |
| Stage II (4) | 1 (25) | 3 (75) | – |
| Stage III (39) | 11 (28) | 19 (49) | 9 (23) |
| Stage IV (19) | 6 (32) | 6 (32) | 7 (36) |
| SCLC | |||
| Limited (11) | 1 (9) | 8 (73) | 2 (18) |
| Extensive (6) | 1 (17) | 4 (66) | 1 (17) |
Stage of NSCLC was not associated with PS score, whether assessed by patient or oncologist (P=0.18). Although there was no statistical difference in PS scores between males and females (P=0.37), oncologists generally gave lower PS scores to female patients (P=0.04, marginally significant). D=doctor-assessed PS score; P=patient-assessed PS score; NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer.